000283120 001__ 283120
000283120 005__ 20260103103704.0
000283120 020__ $$a978-1-0716-5018-9 (print)
000283120 020__ $$a978-1-0716-5019-6 (electronic)
000283120 0247_ $$2doi$$a10.1007/978-1-0716-5019-6_3
000283120 0247_ $$2pmid$$apmid:41478930
000283120 0247_ $$2ISSN$$a1064-3745
000283120 0247_ $$2ISSN$$a1940-6029
000283120 037__ $$aDZNE-2026-00016
000283120 041__ $$aEnglish
000283120 082__ $$a570
000283120 1001_ $$0P:(DE-2719)9003461$$aCampi Santos, Patricia$$b0$$eFirst author$$udzne
000283120 245__ $$aDirect Inoculation of Pathogenic Yeasts into Mouse Lung by Trans-tracheal Instillation.
000283120 260__ $$aNew York, NY$$bSpringer US$$c2026
000283120 29510 $$aModels in Inflammation and Immunopharmacology / Secchim Ribeiro, Lucas (Editor) ; New York, NY : Springer US, 2026, Chapter 3 ; ISSN: 1064-3745=1940-6029 ; ISBN: 978-1-0716-5018-9=978-1-0716-5019-6 ; doi:10.1007/978-1-0716-5019-6
000283120 300__ $$a29 - 42
000283120 3367_ $$2ORCID$$aBOOK_CHAPTER
000283120 3367_ $$07$$2EndNote$$aBook Section
000283120 3367_ $$2DRIVER$$abookPart
000283120 3367_ $$2BibTeX$$aINBOOK
000283120 3367_ $$2DataCite$$aOutput Types/Book chapter
000283120 3367_ $$0PUB:(DE-HGF)7$$2PUB:(DE-HGF)$$aContribution to a book$$bcontb$$mcontb$$s1767364679_32511
000283120 4900_ $$aMethods in Molecular Biology$$v2993
000283120 520__ $$aPathogenic dimorphic fungi are endemic in certain regions and can cause from subclinical infections to systemic mycoses. These pathogens are associated with high mortality and morbidity rates and represent emerging infectious threats to human populations worldwide. Because most fungal pathogens cause lung infection or use the lung as a route to disseminate to other organs, mammalian pulmonary infection models are crucial tools in the advancement of medical mycology. Many different types of animal models of fungal infection have been developed, with murine models being hailed as the gold standard for studies of pathogenesis, to compare virulence between isolates, preclinical evaluation of vaccines and therapies, and host antifungal immune responses. The ability to control numerous variables in performing the model allows for mimicking human disease states and quantitatively monitoring the course of the disease. To model lung inflammation and injury, fungal infectious propagules can be inoculated via intranasal delivery, intratracheal, or aerosolization approaches. The protocol in this chapter details a method for intratracheal delivery of a fungal suspension, where fungal cells are administered directly into the lungs to initiate infection. The aim is to provide a comprehensive description of techniques required to perform mouse pulmonary infection, such that reproducible results are attained, allowing for the use of this in vivo approach for high-quality studies.
000283120 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000283120 588__ $$aDataset connected to CrossRef Book Series, PubMed, , Journals: pub.dzne.de
000283120 650_7 $$2Other$$aFungal infection
000283120 650_7 $$2Other$$aImmune response
000283120 650_7 $$2Other$$aIntratracheal instillation
000283120 650_7 $$2Other$$aMouse model
000283120 650_7 $$2Other$$aPathogenesis
000283120 650_7 $$2Other$$aPulmonary disease
000283120 650_2 $$2MeSH$$aAnimals
000283120 650_2 $$2MeSH$$aMice
000283120 650_2 $$2MeSH$$aDisease Models, Animal
000283120 650_2 $$2MeSH$$aLung: microbiology
000283120 650_2 $$2MeSH$$aLung: pathology
000283120 650_2 $$2MeSH$$aLung Diseases, Fungal: microbiology
000283120 650_2 $$2MeSH$$aLung Diseases, Fungal: pathology
000283120 650_2 $$2MeSH$$aTrachea: microbiology
000283120 773__ $$a10.1007/978-1-0716-5019-6_3
000283120 8564_ $$uhttps://pub.dzne.de/record/283120/files/DZNE-2026-00016_Restricted.pdf
000283120 8564_ $$uhttps://pub.dzne.de/record/283120/files/DZNE-2026-00016_Restricted.pdf?subformat=pdfa$$xpdfa
000283120 909CO $$ooai:pub.dzne.de:283120$$pVDB
000283120 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003461$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000283120 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000283120 9141_ $$y2026
000283120 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-19
000283120 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-19
000283120 9201_ $$0I:(DE-2719)1013008$$kAG Di Monte$$lNeurodegeneration and Neuroprotection in Parkinson´s Disease$$x0
000283120 980__ $$acontb
000283120 980__ $$aVDB
000283120 980__ $$aI:(DE-2719)1013008
000283120 980__ $$aUNRESTRICTED